ArticleHepatology communications2026
Liver test pattern and histologic bile duct injury do not predict response to treatment of immunotherapy hepatotoxicity.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The contemporary epidemiology, causes, and management of drug-induced liver injury.Hepatology communications · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsImmune checkpoint inhibitor (ICI) cholangitis is an uncommon immune-related adverse event affecting the biliary ducts that is considered distinct from ICI hepatitis. This study examines whether the liver injury pattern or presence of histologic bile duct damage determines response to immunosuppression.
methodsThis multicenter retrospective cohort study includes 298 consecutive patients with cancer who received immunotherapy between 2010 and 2021 and were originally classified as grade 3 or higher ICI-related hepatitis [alanine aminotransferase (ALT) ≥ 200 U/L]. Response to immunosuppression was stratified by pattern of liver injury (hepatocellular, cholestatic, or mixed) as defined by R-value, the presence of histologic bile duct damage, and the Drug-Induced Liver Injury Network (DILIN) severity score. The primary outcome was time to normalization of ALT (≤40 U/L). Secondary outcomes included time to grade 1 liver injury (ALT ≤ 100 U/L), need for additional immunosuppression, hospitalization, and death.
resultsThe pattern of liver injury was hepatocellular in 60%, cholestatic in 13%, and mixed in 27%. All patients received corticosteroids as first-line therapy. There was no difference in corticosteroid dose, need for an additional immunosuppressive agent, time to normalization of ALT, or time to grade 1 liver injury between groups. Outcomes were similar among patients with or without histologic bile duct damage and between those with a DILIN severity score of 3+ versus a lower score.
conclusionsThe response of high-grade ICI hepatotoxicity to standard immunosuppression is similar regardless of the pattern of liver injury or the presence of bile duct damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.